Russell Investments Group Ltd. Has $1.27 Million Stake in Harrow, Inc. (NASDAQ:HROW)

Russell Investments Group Ltd. raised its stake in Harrow, Inc. (NASDAQ:HROW) by 138.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 37,712 shares of the company’s stock after acquiring an additional 21,894 shares during the quarter. Russell Investments Group Ltd. owned about 0.11% of Harrow worth $1,265,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Woodmont Investment Counsel LLC lifted its stake in Harrow by 0.5% during the fourth quarter. Woodmont Investment Counsel LLC now owns 81,400 shares of the company’s stock worth $2,731,000 after purchasing an additional 445 shares during the last quarter. Swiss National Bank lifted its position in shares of Harrow by 1.0% during the 4th quarter. Swiss National Bank now owns 59,300 shares of the company’s stock worth $1,990,000 after buying an additional 600 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Harrow by 10.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company’s stock valued at $253,000 after buying an additional 727 shares in the last quarter. HighTower Advisors LLC grew its position in Harrow by 13.8% in the fourth quarter. HighTower Advisors LLC now owns 10,127 shares of the company’s stock valued at $340,000 after acquiring an additional 1,227 shares during the last quarter. Finally, Avantax Advisory Services Inc. raised its stake in Harrow by 11.3% during the fourth quarter. Avantax Advisory Services Inc. now owns 12,534 shares of the company’s stock worth $421,000 after acquiring an additional 1,273 shares in the last quarter. Institutional investors own 72.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. B. Riley reduced their price target on Harrow from $69.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. HC Wainwright reiterated a “buy” rating and set a $57.00 target price on shares of Harrow in a research report on Monday, March 31st.

Harrow Stock Performance

NASDAQ:HROW opened at $23.99 on Monday. Harrow, Inc. has a 52-week low of $9.86 and a 52-week high of $59.23. The business’s fifty day moving average is $26.12 and its 200 day moving average is $35.53. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The firm has a market cap of $855.34 million, a price-to-earnings ratio of -25.52 and a beta of 0.46.

Harrow (NASDAQ:HROW) last posted its quarterly earnings data on Thursday, March 27th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.14. The company had revenue of $66.83 million for the quarter, compared to analysts’ expectations of $66.01 million. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. Research analysts predict that Harrow, Inc. will post -0.53 EPS for the current year.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.